UK researchers advance personalized mRNA cancer vaccine trials

Researchers are making significant progress in developing cancer vaccines using mRNA technology, which was effective during the COVID pandemic. This marks a shift from previous failed trials in cancer vaccine research. The new vaccines will be personalized for each patient, unlike the standard approach used for COVID vaccines. This involves sequencing the patient's cancer tissue to create a tailored vaccine. The UK's NHS has accelerated cancer vaccine trials following the pandemic, with some trials completing ahead of schedule. Results from a key trial are expected by late 2025 or early 2026, potentially leading to the first approved personalized mRNA cancer vaccine.